AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26721259 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 25
Study 23088350 — intervention group
Group type: EXPERIMENTAL
Intervention: α1 noradrenergic blockers + α2 noradrenergic agonists
Number of subjects: 408
Study 23088350 — intervention group
Group type: EXPERIMENTAL
Intervention: benzodiazepines
Number of subjects: 408
Study 23088350 — intervention group
Group type: EXPERIMENTAL
Intervention: voltage-sensitive sodium channel anticonvulsants
Number of subjects: 408
Study 23088350 — intervention group
Group type: EXPERIMENTAL
Intervention: α2δ voltage-sensitive calcium channel blockers
Number of subjects: 408
Study 22265143 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal cross‐linking (CXL) with riboflavin and ultraviolet A (UVA) light
Number of subjects: 39
Study 22265143 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin 0.1% (w/v) eyedrops - 20% dextran solution for 1 month
Number of subjects: 39
Study 22265143 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL and riboflavin eyedrops
Number of subjects: 39
Study 19789444 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 10
Study 19789444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine (4% succinylated gelatin in 0.7% saline)
Number of subjects: 10
Study 19789444 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven (6% hydroxyethyl starch in 0.9% saline)
Number of subjects: 10
Study 19789444 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 10
Study 17413684 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg twice a day
Number of subjects: 199
Study 17413684 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 800 mg twice a day
Number of subjects: 199
Study 17413684 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimized regimens of at least three antiretroviral agents)
Number of subjects: 199
Study 15752409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 microg added to 18 mg hyperbaric ropivacaine
Number of subjects: 31
Study 15752409 — intervention group
Group type: COMPARATOR
Intervention: Saline group (3 ml of 18 mg hyperbaric ropivacaine + 0.5 ml saline)
Number of subjects: 31
Study 12139647 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 30
Study 12139647 — intervention group
Group type: COMPARATOR
Intervention: Nurse presence
Number of subjects: 30
Study 12139647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 11307032 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down therapy with 1200 microg/day of BDP for 4 weeks with short-term oral steroid (prednisolone, 0.5 mg/day for 1 week)
Number of subjects: 82
Study 11307032 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down therapy with 1200 microg/day of BDP for 4 weeks without oral steroids
Number of subjects: 82
Study 11307032 — intervention group
Group type: COMPARATOR
Intervention: Step-up therapy with 400 microg/day of BDP for 4 weeks, then 800 microg/day for another 4 weeks
Number of subjects: 82
Study 11307032 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down therapy with 1200 microg/day of BDP for 4 weeks with short-term oral steroid
Number of subjects: 82
Study 9817114 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone mode
Number of subjects: 0
Study 9817114 — intervention group
Group type: COMPARATOR
Intervention: Mail mode
Number of subjects: 0
Study 8001304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 325
Study 8001304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 3056555 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate mouthrinse
Number of subjects: 51
Study 3056555 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 51
Study 4099843 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseasonal immunization with large doses of ragweed pollen extract
Number of subjects: 21
Study 760587 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 109
Study 760587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (solvent only)
Number of subjects: 109
Study 31119479 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec; STI571) at a fixed dose of 600 mg/D
Number of subjects: 0
Study 31119479 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec; STI571)
Number of subjects: 0
Study 31119479 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31119479 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec; STI571) in patients with 1p/19q‐codeleted tumors
Number of subjects: 0
Study 31119479 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec; STI571) at 600 mg/D
Number of subjects: 0
Study 30368335 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes closed group (participants closed their eyes for 20 min before the test)
Number of subjects: 45
Study 30368335 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes closed group
Number of subjects: 45
Study 30368335 — intervention group
Group type: COMPARATOR
Intervention: Eyes open group (control)
Number of subjects: 45
Study 27358437 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support tool and advance care planning checklist
Number of subjects: 246
Study 27358437 — intervention group
Group type: COMPARATOR
Intervention: Verbal description only (Control)
Number of subjects: 246
Study 24288395 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with 16 mg azelnidipine (O/A group)
Number of subjects: 48
Study 24288395 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment with 1 mg indapamide (O/D group)
Number of subjects: 48
Study 22291207 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin‐pegylated liposomal doxorubicin (CD)
Number of subjects: 0
Study 22291207 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin‐paclitaxel (CP)
Number of subjects: 0
Study 20085177 — intervention group
Group type: EXPERIMENTAL
Intervention: Keishinieppiittokaryojutsubu (KER; decoction) in combination with oral methotrexate (MTX)
Number of subjects: 13
Study 20085177 — intervention group
Group type: EXPERIMENTAL
Intervention: Keishinieppiittokaryojutsubu (KER; decoction)
Number of subjects: 13
Study 17978993 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min brisk walk
Number of subjects: 60
Study 17978993 — intervention group
Group type: COMPARATOR
Intervention: Passive condition
Number of subjects: 60
Study 15289996 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day
Number of subjects: 78
Study 15289996 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 78
Study 12031754 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 20 microg/kg
Number of subjects: 100
Study 12031754 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 40 microg/kg
Number of subjects: 100
Study 12031754 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 11341634 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral lung volume reduction surgery (BLVRS)
Number of subjects: 28
Study 11341634 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 28
Study 7733128 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. thiamine 200 mg/d
Number of subjects: 30
Study 7733128 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 30
Study 1645492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 70 micrograms.kg‐1
Number of subjects: 0
Study 1645492 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 90 micrograms.kg‐1
Number of subjects: 0
Study 6798734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (oral analogue of lidocaine)
Number of subjects: 30
Study 6798734 — intervention group
Group type: COMPARATOR
Intervention: Control (no tocainide)
Number of subjects: 30
Study 30529901 — intervention group
Group type: EXPERIMENTAL
Intervention: So-Pa (sorafenib followed by pazopanib)
Number of subjects: 377
Study 30529901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pa-So (pazopanib followed by sorafenib)
Number of subjects: 377
Study 29131820 — intervention group
Group type: EXPERIMENTAL
Intervention: Single praziquantel treatment
Number of subjects: 446
Study 29131820 — intervention group
Group type: EXPERIMENTAL
Intervention: Two praziquantel treatments
Number of subjects: 446
Study 25708494 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal cavity saline irrigation
Number of subjects: 430
Study 25708494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 430
Study 25835230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chito group (3 g/day chitosan)
Number of subjects: 80
Study 25835230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chito-vita group (3 g/day chitosan plus 2 g/day L-ascorbic acid)
Number of subjects: 80
Study 25835230 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, vehicle only)
Number of subjects: 80
Study 22067628 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 mg intravenous bolus injection followed by continuous infusion at a rate of 0.1 mg/h for 12 hrs; n = 229)
Number of subjects: 457
Study 22067628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 228)
Number of subjects: 457
Study 22067628 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 457
Study 19418868 — intervention group
Group type: COMPARATOR
Intervention: Straumann-conventional (Sc)
Number of subjects: 20
Study 19418868 — intervention group
Group type: COMPARATOR
Intervention: Straumann-Cresco (SCr)
Number of subjects: 20
Study 19418868 — intervention group
Group type: COMPARATOR
Intervention: Brånemark-conventional (Bc)
Number of subjects: 20
Study 19418868 — intervention group
Group type: COMPARATOR
Intervention: Brånemark-Cresco (BCr)
Number of subjects: 20
Study 17217318 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2mg and norethisterone acetate 1mg (Cliane) daily for 6 months
Number of subjects: 40
Study 17217318 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet daily for 6 months
Number of subjects: 40
Study 16025025 — intervention group
Group type: EXPERIMENTAL
Intervention: TDR with the CHARITE artificial disc
Number of subjects: 304
Study 16025025 — intervention group
Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion with BAK cages and iliac crest bone graft
Number of subjects: 304
Study 12355489 — intervention group
Group type: EXPERIMENTAL
Intervention: Raynaud's Condition Score (RCS) for RP activity (possible range 0-10)
Number of subjects: 281
Study 12355489 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 281
Study 12355489 — intervention group
Group type: EXPERIMENTAL
Intervention: AIMS2 mood and tension subscales
Number of subjects: 281
Study 12355489 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scales (VAS) for SSc/RP-related measures
Number of subjects: 281
Study 12355489 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily diaries documenting frequency and duration of RP attacks
Number of subjects: 281
Study 12355489 — intervention group
Group type: EXPERIMENTAL
Intervention: Global assessment scales by physicians
Number of subjects: 281
Study 12355489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to change of RP measures
Number of subjects: 281
Study 10206791 — intervention group
Group type: EXPERIMENTAL
Intervention: Td-eIPV (single dose)
Number of subjects: 368
Study 10206791 — intervention group
Group type: EXPERIMENTAL
Intervention: Td-eIPV (two doses)
Number of subjects: 368
Study 10206791 — intervention group
Group type: EXPERIMENTAL
Intervention: Td-eIPV (safety data)
Number of subjects: 368
Study 8547401 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2203699 — intervention group
Group type: EXPERIMENTAL
Intervention: Large data sets for outcome assessment
Number of subjects: 0
Study 2203699 — intervention group
Group type: EXPERIMENTAL
Intervention: Data base evaluations
Number of subjects: 0
Study 2203699 — intervention group
Group type: EXPERIMENTAL
Intervention: Data base analyses
Number of subjects: 0
Study 649013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolo Mobilat film tablets
Number of subjects: 50
Study 649013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30112716 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 45
Study 30112716 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 45
Study 27632854 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training sessions with a frequency of 30 Hz and an amplitude of 3 mm
Number of subjects: 20
Study 27632854 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training sessions
Number of subjects: 20
Study 27632854 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol (turned-off vibration plate)
Number of subjects: 20
Study 24657352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-maximal force control in young adults
Number of subjects: 32
Study 24657352 — intervention group
Group type: COMPARATOR
Intervention: Sub-maximal force control in older adults
Number of subjects: 32
Study 24657352 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter structural integrity measures (fractional anisotropy and radial diffusivity)
Number of subjects: 32
Study 23020939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen axetil (50 mg)
Number of subjects: 200
Study 23020939 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular tramadol (100 mg)
Number of subjects: 200
Study 19789197 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 3MS score
Number of subjects: 1793
Study 19789197 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in 3MS and PPM
Number of subjects: 1793
Study 19789197 — intervention group
Group type: COMPARATOR
Intervention: Baseline PPMs
Number of subjects: 1793
Study 17631131 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 3
Study 17631131 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 3
Study 17631131 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen 800 mg 3 times daily
Number of subjects: 3
Study 16202199 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite resin (Z100, 3M ESPE)
Number of subjects: 40
Study 16202199 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect ceramic inlay (IPS Empress, Ivoclar‐Vivadent)
Number of subjects: 40
Study 16202199 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth
Number of subjects: 40
Study 16202199 — intervention group
Group type: COMPARATOR
Intervention: Unrestored teeth (MOD cavity preparation)
Number of subjects: 40
Study 11856097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype slim flexible cystoscope
Number of subjects: 200
Study 11856097 — intervention group
Group type: COMPARATOR
Intervention: Standard flexible cystoscope
Number of subjects: 200
Study 10442212 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed coffee samples (Darboven improvement procedure)
Number of subjects: 18
Study 10442212 — intervention group
Group type: COMPARATOR
Intervention: Non-processed coffee samples
Number of subjects: 18
Study 7496880 — intervention group
Group type: COMPARATOR
Intervention: Information or utilization management intervention (e.g., patients or physician education, telephone follow‐up, patient or physician reminders, home care services)
Number of subjects: 600
Study 2186324 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (MP)
Number of subjects: 136
Study 2186324 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex)
Number of subjects: 136
Study 378350 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI), 100 rads in 10 fractions over 12 days plus combination chemotherapy (CVP or C-MOPP)
Number of subjects: 39
Study 378350 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (CVP or C-MOPP) alone
Number of subjects: 39
Study 30444673 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐HBV‐IPV/Hib
Number of subjects: 585
Study 30444673 — intervention group
Group type: COMPARATOR
Intervention: DTaP‐HBV‐IPV+ HibA
Number of subjects: 585
Study 30444673 — intervention group
Group type: COMPARATOR
Intervention: DTaP‐IPV/Hib+ HBV
Number of subjects: 585
Study 30444673 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 585
Study 28287044 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (Forsteo, 20 μg daily for 2 months postoperatively)
Number of subjects: 50
Study 28287044 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 50
Study 25763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-guided fitness (MOV)
Number of subjects: 52
Study 25763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fitness (FIT)
Number of subjects: 52
Study 25763518 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 52
Study 24341511 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback plus worksheet
Number of subjects: 4055
Study 24341511 — intervention group
Group type: COMPARATOR
Intervention: Feedback alone
Number of subjects: 4055
Study 24341511 — intervention group
Group type: COMPARATOR
Intervention: Feedback plus worksheet and feedback alone
Number of subjects: 4055
Study 21756808 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib plus Hyper-CVAD chemotherapy
Number of subjects: 18
Study 21756808 — intervention group
Group type: COMPARATOR
Intervention: Control (no allogeneic hematopoietic stem cell transplantation)
Number of subjects: 18
Study 19339534 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert (Jeneric/Pentron)
Number of subjects: 33
Study 19339534 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil (Dentsply/Caulk)
Number of subjects: 33
Study 16423143 — intervention group
Group type: EXPERIMENTAL
Intervention: Early psychological intervention using a psychological debriefing format
Number of subjects: 158
Study 16423143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early psychological intervention)
Number of subjects: 158
Study 12938838 — intervention group
Group type: EXPERIMENTAL
Intervention: Superelastic wire with a force plateau of 0.8‐1 N, activated initially by 4.5 mm and not reactivated during 12 weeks.
Number of subjects: 27
Study 12938838 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel wire with a buccal offset of 1 mm, reactivated every four weeks.
Number of subjects: 27
Study 10950448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (alpha-tocopherol 1200 IU x day(-1))
Number of subjects: 14
Study 10950448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9018408 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone propionate
Number of subjects: 12
Study 9018408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10184318 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodropropizine (LD) 60 mg t.i.d. as oral drops for 8 days
Number of subjects: 30
Study 10184318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2900919 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA 100 mg plus heparin
Number of subjects: 2516
Study 2900919 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus heparin
Number of subjects: 2516
Study 29490105 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Breakfast Consumption (DBC)
Number of subjects: 27
Study 29490105 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Breakfast Consumption (IBC)
Number of subjects: 27
Study 25710923 — intervention group
Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer Diabetes (guided self-help intervention, n = 130)
Number of subjects: 260
Study 25710923 — intervention group
Group type: COMPARATOR
Intervention: Brief online unguided psychoeducation program for depression (control group, n = 130)
Number of subjects: 260
Study 22084404 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR(BC)
Number of subjects: 82
Study 22084404 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 82
Study 20133925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-conserving devices at 2 L O(2)/min
Number of subjects: 13
Study 20133925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-conserving devices during exertion
Number of subjects: 13
Study 20133925 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 13
Study 20133925 — intervention group
Group type: EXPERIMENTAL
Intervention: Two systems providing less oxygen than predicted
Number of subjects: 13
Study 20133925 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous setting of oxygen pulse volume
Number of subjects: 13
Study 18991094 — intervention group
Group type: EXPERIMENTAL
Intervention: TT homozygotes
Number of subjects: 44
Study 18991094 — intervention group
Group type: EXPERIMENTAL
Intervention: Early septic patients
Number of subjects: 44
Study 18991094 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulation (in vitro)
Number of subjects: 44
Study 16466167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Granule (BSG) combined with Marine Injection (MI)
Number of subjects: 90
Study 16466167 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (control)
Number of subjects: 90
Study 12502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen plugs
Number of subjects: 61
Study 12502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone plugs
Number of subjects: 61
Study 12502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing agent usage
Number of subjects: 61
Study 12502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal/conjunctival fluorescein staining
Number of subjects: 61
Study 12502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 61
Study 12502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular comfort
Number of subjects: 61